ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL595
CHEMBL595
Compound Name PIOGLITAZONE
ChEMBL Synonyms GLIZOFAR | U-72107A | PIOGLITAZONE | GLIDIPION | PIOGLITAZONE HYDROCHLORIDE | Actos | Duetact | DIABIOM
Max Phase 4 (Approved)
Trade Names ACTOS | PIOGLITAZONE HYDROCHLORIDE | GLIDIPION | GLIZOFAR | DIABIOM
Molecular Formula C19H20N2O3S

Additional synonyms for CHEMBL595 found using NCI Chemical Identifier Resolver

Compound Representations

Molfile Download MolFile
Canonical SMILES CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1
Standard InChI InChI=1S/C19H20N2O3S/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4- ...
Download InChI
Standard InChI Key HYAFETHFCAUJAY-UHFFFAOYSA-N

Sources

  • AstraZeneca Deposited Data
  • British National Formulary
  • Deposited Supplementary Bioactivity Data
  • DrugMatrix
  • Orange Book
  • PubChem BioAssays
  • Scientific Literature
  • TP-search Transporter Database
  • USP Dictionary of USAN and International Drug Names
  • WHO Anatomical Therapeutic Chemical Classification

Alternate Forms of Compound in ChEMBL


CHEMBL595

Molecule Features

CHEMBL595 compound icon
Drug Type:Synthetic Small Molecule Rule of Five:Y First In Class:N Chirality:Racemic Mixture Prodrug:N Oral:Y Parenteral:N Topical:N Black Box:Y Availability Type:Prescription-only

Mechanism of Action

Mechanism of Action ChEMBL Target References
Peroxisome proliferator-activated receptor gamma agonist Peroxisome proliferator-activated receptor gamma DailyMed

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
AnemiaD000740EFO:0004272anemia1ClinicalTrials
Glucose IntoleranceD018149EFO:0002546abnormal glucose tolerance2ClinicalTrials
Hepatitis C, ChronicD019698EFO:0004220Chronic Hepatitis C infection2ClinicalTrials
Multiple Sclerosis, Relapsing-RemittingD020529EFO:0003929relapsing-remitting multiple sclerosis1ClinicalTrials
Alzheimer DiseaseD000544EFO:0000249Alzheimers disease2ClinicalTrials
Carcinoma, Non-Small-Cell LungD002289EFO:0003060non-small cell lung carcinoma2ClinicalTrials
ClinicalTrials
Child Development Disorders, PervasiveD002659EFO:0003756autism spectrum disorder2ClinicalTrials
Diabetes Mellitus, Type 2D003924EFO:0001360type II diabetes mellitus4ClinicalTrials
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
DailyMed
Friedreich AtaxiaD005621Orphanet:95Friedreich ataxia3ClinicalTrials
HIV-Associated Lipodystrophy SyndromeD039682EFO:1001348HIV-Associated Lipodystrophy Syndrome3ClinicalTrials
Kidney DiseasesD007674EFO:0003086kidney disease2ClinicalTrials
Leukemia, Myeloid, AcuteD015470EFO:0000222acute myeloid leukemia2ClinicalTrials
Renal Insufficiency, ChronicD051436EFO:0003884chronic kidney disease2ClinicalTrials
ClinicalTrials
Amyotrophic Lateral SclerosisD000690EFO:0000253amyotrophic lateral sclerosis2ClinicalTrials
ClinicalTrials
Cerebral HemorrhageD002543EFO:0005669intracerebral hemorrhage2ClinicalTrials
Depressive DisorderD003866EFO:0003761unipolar depression2ClinicalTrials
ClinicalTrials
Diabetes MellitusD003920EFO:0000400diabetes mellitus4ATC
ClinicalTrials
Hepatitis CD006526EFO:0003047hepatitis C infection2ClinicalTrials
InfectionD007239EFO:0000544infection2ClinicalTrials
InflammationD007249MP:0001845inflammation0ClinicalTrials
Leukemia, Myelogenous, Chronic, BCR-ABL PositiveD015464EFO:0000339chronic myelogenous leukemia2ClinicalTrials
Multiple SclerosisD009103EFO:0003885multiple sclerosis1ClinicalTrials
Prostatic NeoplasmsD011471EFO:0001663prostate carcinoma2ClinicalTrials
AsthmaD001249EFO:0000270asthma2ClinicalTrials
Cystic FibrosisD003550Orphanet:586Cystic fibrosis1ClinicalTrials
Diabetes Mellitus, Type 1D003922EFO:0001359type I diabetes mellitus1ClinicalTrials
Lupus Erythematosus, SystemicD008180EFO:0002690systemic lupus erythematosus1ClinicalTrials
Metabolic SyndromeD024821EFO:0000195metabolic syndrome3ClinicalTrials
Parkinson DiseaseD010300EFO:0002508Parkinson's disease2ClinicalTrials
Cognitive DysfunctionD060825HP:0100543cognitive impairment2ClinicalTrials
Liver DiseasesD008107EFO:0001421liver disease3ClinicalTrials
MeningiomaD008579Orphanet:2495Meningioma1ClinicalTrials
NeoplasmsD009369EFO:0000616neoplasm1ClinicalTrials
Non-alcoholic Fatty Liver DiseaseD065626EFO:0003095non-alcoholic fatty liver disease2ClinicalTrials
ClinicalTrials
Pulmonary Alveolar ProteinosisD011649HP:0006517Alveolar proteinosis1ClinicalTrials
Carcinoma, Squamous CellD002294EFO:0000707squamous cell carcinoma2ClinicalTrials
GlioblastomaD005909EFO:0000519glioblastoma multiforme1ClinicalTrials
HepatitisD006505HP:0012115hepatitis2ClinicalTrials
Opioid-Related DisordersD009293EFO:0005611opioid dependence2ClinicalTrials
Pancreatic NeoplasmsD010190EFO:0002618pancreatic carcinoma2ClinicalTrials
ClinicalTrials
Polycystic Ovary SyndromeD011085EFO:0000660polycystic ovary syndrome0ClinicalTrials
StrokeD020521EFO:0000712stroke2ClinicalTrials
Thyroid NeoplasmsD013964EFO:0002892thyroid carcinoma2ClinicalTrials
Carcinoma, Squamous CellD002294EFO:0000708squamous cell lung carcinoma2ClinicalTrials
Fatty LiverD005234HP:0001397Hepatic steatosis3ClinicalTrials
Lung NeoplasmsD008175EFO:0001071lung carcinoma2ClinicalTrials
MelanomaD008545EFO:0000756melanoma1ClinicalTrials
Non-alcoholic Fatty Liver DiseaseD065626EFO:1001249non-alcoholic steatohepatitis2ClinicalTrials
PsoriasisD011565EFO:0000676psoriasis2ClinicalTrials
Leukoplakia, OralD007972HP:0002745Oral leukoplakia2ClinicalTrials
AlcoholismD000437EFO:0003829alcohol dependence2ClinicalTrials
Arthritis, RheumatoidD001172EFO:0000685rheumatoid arthritis3ClinicalTrials
AstrocytomaD001254EFO:0002499anaplastic astrocytoma1ClinicalTrials
Cardiovascular DiseasesD002318EFO:0000319cardiovascular disease2ClinicalTrials
Crohn DiseaseD003424EFO:0000384Crohn's disease1ClinicalTrials
Granulomatous Disease, ChronicD006105Orphanet:379Chronic granulomatous disease1ClinicalTrials
Hypertension, PulmonaryD006976EFO:0001361pulmonary hypertension2ClinicalTrials
Multiple MyelomaD009101EFO:0001378multiple myeloma1ClinicalTrials
ObesityD009765EFO:0001073obesity2ClinicalTrials
Peripheral Arterial DiseaseD058729EFO:0004265peripheral arterial disease0ClinicalTrials
Prostatic NeoplasmsD011471EFO:0000673prostate adenocarcinoma2ClinicalTrials

Clinical Data

ClinicalTrials.gov PIOGLITAZONE
The Cochrane Collaboration PIOGLITAZONE

Compound Bioactivity Summary

Compound Assay Summary

Compound Target Summary

Target Predictions

The two tables below display ChEMBL single-protein targets which are predicted to interact with CHEMBL595. A 1uM and 10 uM cut-off have been applied to ChEMBL bioactivity data used to generate the respective models and the yellow coloured rows correspond to genuine predictions, i.e. targets not included in the original training set for this compound.


1uM


ChEMBL_ID Target Name Organism Score
CHEMBL2459 Peroxisome proliferator-activated receptor gamma Mus musculus 1.000
CHEMBL235 Peroxisome proliferator-activated receptor gamma Homo sapiens 0.999
CHEMBL4422 Free fatty acid receptor 1 Homo sapiens 0.998
CHEMBL1795168 CDGSH iron-sulfur domain-containing protein 1 Homo sapiens 0.996
CHEMBL239 Peroxisome proliferator-activated receptor alpha Homo sapiens 0.837

10uM


ChEMBL_ID Target Name Organism Score
CHEMBL4422 Free fatty acid receptor 1 Homo sapiens 1.000
CHEMBL2459 Peroxisome proliferator-activated receptor gamma Mus musculus 1.000
CHEMBL235 Peroxisome proliferator-activated receptor gamma Homo sapiens 0.999
CHEMBL1795168 CDGSH iron-sulfur domain-containing protein 1 Homo sapiens 0.987
CHEMBL239 Peroxisome proliferator-activated receptor alpha Homo sapiens 0.969

Calculated Compound Parent Properties

Mol. Weight Mol. Weight Monoisotopic ALogP #Rotatable Bonds Polar Surface Area Molecular Species
356.5 356.1195 3.16 7 68.29 ACID


HBA HBD #Ro5 Violations HBA (Lipinski) HBD (Lipinski) #Ro5 Violations (Lipinski)
5 1 0 5 1 0


ACD Acidic pKa ACD Basic pKa ACD LogP ACD LogD pH7.4 Aromatic Rings Heavy Atoms QED Weighted
6.35 5.53 3.5 2.45 2 25 0.83

Structural Alerts

There are 2 structural alerts for CHEMBL595. To view alerts please click here.

Compound Cross References

ATC A - ALIMENTARY TRACT AND METABOLISM
A10 - DRUGS USED IN DIABETES
A10B - BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10BG - Thiazolidinediones
A10BG03 - pioglitazone

ChemSpider ChemSpider:HYAFETHFCAUJAY-UHFFFAOYSA-N
DailyMed pioglitazone hydrochloride
PubChem SID: 137275816 SID: 174007207 SID: 26756476
Wikipedia Pioglitazone

UniChem Cross References

View the UniChem Connectivity matches for CHEMBL595



ACToR 105355-27-9 111025-46-8
Atlas pioglitazone
Brenda 6203 83443
ChEBI 8228
DrugBank DB01132
DrugCentral 2179
eMolecules 902308
EPA CompTox Dashboard DTXSID3037129
Guide to Pharmacology 2694
Human Metabolome Database HMDB0015264
KEGG Ligand C07675
LINCS LSM-1592
Mcule MCULE-2346786634
MolPort MolPort-002-508-211 MolPort-028-603-922
Nikkaji J277.717G
PharmGKB PA450970
PubChem 4829
PubChem: Drugs of the Future 22395182
PubChem: Thomson Pharma 14828061
Selleck pioglitazone-actos
SureChEMBL SCHEMBL4121

UniChem REST Service Call:
https://www.ebi.ac.uk/unichem/rest/verbose_inchikey/HYAFETHFCAUJAY-UHFFFAOYSA-N spacer
spacer